BRCA2 and pancreatic neoplasm: Approximately 20% of ovarian cancer patients, 10% of breast cancer patients, 5% of pancreatic cancer patients, and 0.5%–2% of prostate cancer patients have an underlying BRCA1 or BRCA2 mutation.2-6 Identification of probands with a pathogenic germline mutation allows for cascade testing of relatives and prevention of future disease through surveillance and/or prophylactic surgery.